Three-year HNSCC data boost Bicara (NASDAQ: BCAX) ficerafusp program
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Bicara Therapeutics reported three-year follow-up data from its Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. At the pivotal 1500mg weekly dose, the combination showed an estimated 31% overall survival at three years, approximately doubling survival versus a retrospective standard-of-care pembrolizumab analysis.
Across 750mg weekly, 1500mg weekly and 2000mg every-other-week cohorts, confirmed response rates ranged from 48–57%, with complete response rates of 13%, 25% and 30% as of March 31, 2026. Deep responses of at least 80% tumor shrinkage were common at higher doses and were associated with longer duration of response, progression-free survival and overall survival. Bicara highlighted biomarker data supporting TGF-β inhibition as the driver of these deep, durable responses and noted that the pivotal FORTIFI-HN01 Phase 2/3 study and an alternate dosing study are ongoing or planned.
Positive
- Three-year survival signal at pivotal dose: At 1500mg weekly, ficerafusp alfa plus pembrolizumab showed an estimated 31% overall survival at three years, approximately doubling survival versus a retrospective standard-of-care pembrolizumab analysis in HPV-negative patients.
- High rates of deep, durable responses: Across cohorts, confirmed response rates were 48–57%, with complete responses up to 30% and deep (≥80%) tumor shrinkage in most responders at higher doses, alongside prolonged PFS and DOR.
- Depth of response linked to long-term outcomes: Deep responders had median duration of response of 31.6 months and median PFS of 36.9 months, with reported 65% and 63% risk reductions for progression/death and death versus partial responders, supporting depth of response as a surrogate for long-term benefit.
Negative
- None.
Insights
Early-phase head and neck cancer data show deep, durable responses that support Bicara’s ongoing pivotal program.
Bicara Therapeutics released extended Phase 1/1b results for ficerafusp alfa plus pembrolizumab in first-line HPV-negative HNSCC. At 1500mg weekly, estimated three-year overall survival was 31%, described as roughly double a retrospective pembrolizumab standard-of-care analysis. Confirmed response rates across dose cohorts were 48–57%, with deep tumor shrinkage in many patients.
The dataset links TGF-β inhibition to greater tumor penetration and immune activation, with deep responders (≥80% shrinkage) achieving a median duration of response of 31.6 months and median progression-free survival of 36.9 months. Risk reductions of 65% for progression or death and 63% for death versus partial responders are notable, while safety was described as generally well tolerated with no new signals.
The results remain from a relatively small Phase 1/1b population, and cross-trial comparisons to historical controls have inherent limitations. Even so, the data help justify the ongoing FORTIFI-HN01 pivotal Phase 2/3 trial and an upcoming alternate dosing study, with future readouts from these later-stage trials needed to determine whether the benefits translate into registrational outcomes.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Three-year overall survival at 1500mg: 31% OS at three years
Confirmed overall response rate 750mg: 57%
Confirmed overall response rate 1500mg: 54%
+5 more
8 metrics
Three-year overall survival at 1500mg
31% OS at three years
1500mg weekly ficerafusp alfa plus pembrolizumab dose cohort
Confirmed overall response rate 750mg
57%
750mg weekly cohort in Phase 1/1b study
Confirmed overall response rate 1500mg
54%
1500mg weekly cohort in Phase 1/1b study
Confirmed overall response rate 2000mg
48%
2000mg every-other-week cohort
Complete response rates by dose
13%, 25%, 30%
CR at 750mg QW, 1500mg QW, 2000mg Q2W as of March 31, 2026
Median DOR at 1500mg
21.7 months
Duration of response in 1500mg weekly cohort
Deep responders median DOR
31.6 months
Pooled deep responders with ≥80% tumor shrinkage
Deep responders median PFS
36.9 months
Pooled analysis of deep responders vs partial responders
Key Terms
Breakthrough Therapy Designation, progression-free survival (PFS), overall survival (OS), TGF-β inhibition, +2 more
6 terms
Breakthrough Therapy Designation regulatory
"The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ficerafusp alfa in combination with pembrolizumab"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
progression-free survival (PFS) financial
"deep responses translated into durable long-term outcomes across DOR, PFS, and OS"
Progression-free survival (PFS) measures the length of time in a clinical trial or treatment period during which a patient’s disease does not get worse. Investors watch PFS because longer PFS in trials can signal a drug’s effectiveness, influence regulatory approval and reimbursement decisions, and affect commercial value—think of it as how long a product keeps a problem from returning, which helps estimate future sales and competitive advantage.
overall survival (OS) financial
"demonstrated differentiated three-year overall survival and deep responses driven by TGF-β inhibition"
Overall survival (OS) is the length of time from the start of a treatment or clinical study until death from any cause, essentially measuring how long patients live after a therapy begins. Investors watch OS because it is the most direct evidence a treatment extends life; stronger OS results can drive regulatory approvals, wider use and higher revenue expectations, much like sales figures proving a product actually works.
TGF-β inhibition medical
"deep responses driven by TGF-β inhibition in 1L R/M HPV-negative HNSCC"
TGF‑β inhibition is the deliberate blocking of transforming growth factor‑beta, a naturally occurring protein that helps regulate cell growth, immune behavior and scar formation. For investors, drugs that inhibit TGF‑β can change the course of diseases such as certain cancers, fibrosis and immune disorders, so progress or setbacks in these programs can have large impacts on a biotech company's value, much like a breakthrough or failure in a disruptive technology.
head and neck squamous cell carcinoma (HNSCC) medical
"first-line (1L) recurrent/metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC)"
Head and neck squamous cell carcinoma (HNSCC) is a common type of cancer that arises from the flat, thin cells lining the mouth, throat, voice box and nearby areas. It matters to investors because diagnosis, treatment and clinical trial progress directly affect the commercial prospects of drugs, diagnostics and medical services; a successful new therapy can lift a company’s revenue outlook while failed trials can hurt valuations — like a weather forecast that shifts a company’s expected future.
tumor microenvironment (TME) medical
"within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor"
The tumor microenvironment (TME) is the immediate surrounding area of a tumor, including nearby cells, blood vessels, and supporting tissues that interact with the cancer cells. It plays a crucial role in how a tumor grows and spreads, much like how the environment around a plant influences its health and development. For investors, understanding the TME is important because it affects the success of treatments and innovations in cancer therapies, impacting the potential value of related biotech companies.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 21, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 - Other Events.
On May 21, 2026, Bicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits
(d) The following exhibits are being filed herewith:
Exhibit No. | Description | |||||||
99.1 | Press Release, dated May 21, 2026. | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bicara Therapeutics Inc. | |||||||||||
Date: May 21, 2026 | By: | /s/ Claire Mazumdar | |||||||||
Name: | Claire Mazumdar, Ph.D. | ||||||||||
Title: | Chief Executive Officer | ||||||||||
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
Phase 1b dataset of ~90 patients in 1L R/M HPV-negative HNSCC across all three doses demonstrated that deep responses translated into durable long-term outcomes across DOR, PFS, and OS, with a generally well-tolerated safety profile and no new safety signals
Pooled analyses reinforced the TGF-β contribution and demonstrated that deep responders have greater durability of response and appeared more likely to remain progression-free and alive
Company to host conference call and webcast on Friday, May 22, 2026 at 8:30 a.m. ET
BOSTON, May 21, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced extended follow-up data out to three years from the Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab in first-line (1L) recurrent/metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). The data, which included the 750mg weekly (QW), 1500mg QW, and 2000mg every-other-week (Q2W) expansion cohorts, demonstrated deep, durable responses observed to be driven by TGF-β inhibition. The data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Ficerafusp alfa is a bifunctional epidermal growth factor receptor (EGFR)-directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap designed to enable increased tumor penetration to drive deep and durable responses and potentially improve survival outcomes. Bicara is currently evaluating ficerafusp alfa at 1500mg QW in combination with pembrolizumab in the Phase 3 portion of the ongoing FORTIFI-HN01 pivotal study. Additionally, the company plans to initiate a study evaluating a 12-week loading dose followed by a 2250mg every-three-weeks maintenance dose regimen in the third quarter of 2026 to support long-term administration.
“Ficerafusp alfa continued to deliver deep, durable responses with up to three years of follow-up in 1L R/M HPV-negative HNSCC, reinforcing its best-in-class potential in this setting. At our pivotal study dose of 1500mg QW, an estimated one in three patients was alive at three years – approximately doubling the survival rate observed in retrospective analysis with standard of care pembrolizumab in HPV-negative patients,” said Bill Schelman, M.D., Ph.D., Chief Medical Officer of Bicara Therapeutics. “TGF-β inhibition was observed to be the mechanistic foundation of this clinical benefit: driving tumor penetration, enabling immune cell infiltration, and translating depth of response into durable, long-term survival – a clinical profile no other EGFR-directed therapy in head and neck cancer has demonstrated.”
Up to three years of follow-up reinforces ficerafusp alfa’s best-in-class potential in 1L R/M HPV-negative HNSCC
Across all dose cohorts of ficerafusp alfa in combination with pembrolizumab, the data demonstrated deep, durable responses and a generally well-tolerated safety profile. All three dose cohorts also demonstrated clinically meaningful duration of response (DOR), progression-free survival (PFS) and overall survival (OS), representing substantial improvements over standard of care treatment.
Notably, complete response (CR) rates have continued to mature across all three cohorts since prior data presentation - increasing to 13% at 750mg QW, 25% at 1500mg QW, and 30% at 2000mg Q2W as of the March 31, 2026 data snapshot.
Additionally, deep responses of at least 80% tumor shrinkage were observed at doses of ficerafusp alfa that resulted in greater TGF-β inhibition and tumor penetration, with more than three-fourths of responders in the 1500mg QW and 2000mg Q2W cohorts achieving deep responses.
Three-year follow-up from the 1500mg QW dose cohort, as of the March 31, 2026 data snapshot, showed an estimated OS rate of 31%, approximately doubling the survival rate observed in retrospective analysis with standard of care pembrolizumab in HPV-negative patients.1
Table 1. Key Efficacy Results Across Ficerafusp Alfa Dose Cohorts in Combination with Pembrolizumab in 1L R/M HPV-Negative HNSCC
750mg QW (n=30) | 1500mg QW (n=28) | 2000mg Q2W (n=27) | |||||||||
Confirmed overall response rate | 57% | 54% | 48% | ||||||||
CR rate | 13% | 25% | 30% | ||||||||
Deep (≥80%) responses | 47% | 80% | 77% | ||||||||
Median time to response | 1.6 months | 1.4 months | 1.6 months | ||||||||
Median DOR | NR (>16.6 months) | 21.7 months | NR (>12.8 months) | ||||||||
Median PFS | 6.9 months | 9.9 months | 12.7 months | ||||||||
Median OS | NM (>19.4 months) | 21.3 months | NM (>12.7 months; >23.6 months in patients with > 2-year follow-up)* | ||||||||
Data snapshot as of March 31, 2026. NR = not reached; NM = not mature
*Data maturation reflects a bimodal enrollment distribution: in the initial 15 efficacy evaluable patients (median follow-up: 27 months) median OS is not mature but has surpassed 23.6 months. The remaining 12 efficacy evaluable patients had a median follow-up of 11.7 months.
TGF-β inhibition drove depth and durability of response
Biomarker analyses across all three dose cohorts demonstrated sustained TGF-β inhibition and immune activation with ficerafusp alfa, reinforcing the mechanistic link between intra-tumoral TGF-β inhibition, immune activation, and the deep, durable responses.
Deep responses translated to improved durability and long-term outcomes for patients
Ficerafusp alfa’s depth of response, as demonstrated by CR rates and proportion of deep responders, has been well-established and is clinically differentiating. The updated data further reinforced depth of response as a driver of long-term outcomes in patients with 1L R/M HPV-negative HNSCC. Across a pooled cohort analysis, two-thirds of responders achieved deep responses of greater than 80% tumor shrinkage and experienced more durable disease control, with meaningfully longer DOR, PFS, and OS compared to patients with partial responses of less than 80% tumor shrinkage.
Across the pooled analysis comparing deep responders to partial responders of less than 80% tumor shrinkage, deep responders demonstrated:
•A median DOR of 31.6 months;
•A median PFS of 36.9 months, with a 65% reduction in the risk of disease progression or death; and
•A median OS that has not been reached, with a 63% reduction in the risk of death.
This updated dataset provides compelling evidence for depth of response as a clinical surrogate for differentiated long-term outcomes with ficerafusp alfa treatment.
ASCO 2026 Poster Presentations
Annual Meeting | Chicago, IL | May 30 – June 3, 2026
Poster 1 (Wong et al.): Sustained Depth and Durability of Response with TGF-β Trapping in 1L R/M HPV-Negative HNSCC
Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab
Authors: Wong DJ, et al. | Abstract #6040 | Poster Board: 497 | May 30, 2026, 1:30-4:30 p.m. CDT
Poster 2 (Kaczmar et al.): Impact of Depth of Response on Long-Term Clinical Outcomes
The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
Authors: Kaczmar J, et al. | Abstract #6058| Poster Board: 515 | May 30, 2026, 1:30-4:30 p.m. CDT
Poster 3 (Ferrarotto et al.): FORTIFI-HN01 Trial in Progress
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01
Authors: Ferrarotto R, et al. | Abstract #TPS6129| Poster Board: 584A | May 30, 2026, 1:30-4:30 p.m. CDT
1. Based on a retrospective analysis of Supplementary Figure 1C, Vasiliadou, Ifigenia, et al. International Journal of Cancer 155.5 (2024): 883-893. No head-to-head studies have been conducted, and cross-trial comparisons differences in molecule composition, trial design, and patient population and characteristics.
Conference Call Information
Bicara will host a live conference call and webcast on Friday, May 22, 2026 at 8:30 a.m. ET. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive
dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.
About Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinomas (HNSCCs) develop from the mucosal epithelium in the oral cavity, pharynx and larynx and are the most common malignancies that arise in the head and neck. HNSCC is one of the most common cancers in the United States and globally with a rising incidence anticipated to reach one million new global cases annually by 2030. Ten percent of HNSCC patients are diagnosed with metastatic disease and up to 30% develop a recurrence or metastases over time after receiving initial treatment for advanced HNSCC. Most cases of HNSCC are thought to result from accumulated mutations caused by carcinogenic exposures such as tobacco smoke or HPV infection. Approximately 80% of patients with R/M HNSCC are HPV-negative. These HPV-negative tumors often exhibit a recurrence pattern that is primarily local and are associated with severe morbidities, including fatal tumor bleeding, intense pain, difficulty swallowing, significant weight loss, and cachexia. This highlights a critical unmet need for therapies that have the potential to deliver durable anti-tumor responses, ultimately leading to meaningful improvements in patients' quality of life.
About Ficerafusp Alfa
Ficerafusp alfa is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. Ficerafusp alfa is currently being evaluated in FORTIFI-HN01, a pivotal Phase 2/3 clinical trial in patients with 1L R/M HNSCC.
About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant
unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding Bicara’s strategy, business plans and focus; the clinical development of ficerafusp alfa, including the initiation, timing, progress, results and future data releases of Bicara’s ongoing and planned clinical trials; the advancement of the FORTIFI-HN01 pivotal trial in 1L HPV-negative R/M HNSCC and the ongoing Phase 1/1b expansion cohorts; the initiation of an alternate dose study in the third quarter of 2026 to evaluate a loading and every-three-week maintenance dosing regimen of ficerafusp alfa; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability, tolerability and overall survival as compared to the existing standard of care; and the potential for regulatory approval and U.S. launch of ficerafusp alfa. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks relating to Bicara’s research and development activities; Bicara’s ability to execute on its business plans and strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to the clinical development of ficerafusp alfa; the Company’s dependence on third parties; risks related to the Company’s financial condition and need for additional funds in order to commercialize ficerafusp alfa, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Bicara’s intellectual property protections; and risks related to the competitive landscape for ficerafusp alfa; as well as other risks described in “Risk Factors,” in Bicara’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Bicara’s subsequent filings with the U.S. Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Contacts
Investors
Rachel Frank
IR@bicara.com
Rachel Frank
IR@bicara.com
Media
Tim Palmer
tim.palmer@bicara.com
Tim Palmer
tim.palmer@bicara.com
FAQ
What clinical results did Bicara Therapeutics (BCAX) report for ficerafusp alfa?
Bicara reported three-year follow-up from a Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line HPV-negative HNSCC, showing deep, durable responses and an estimated 31% overall survival at three years at the 1500mg weekly dose.
How strong were response rates for Bicara’s ficerafusp alfa combination in HNSCC?
Confirmed overall response rates ranged from 48–57% across the 750mg weekly, 1500mg weekly, and 2000mg every-other-week cohorts, with complete response rates of 13%, 25%, and 30%, and many patients achieving deep tumor shrinkage of at least 80%.
How does the 31% three-year overall survival with ficerafusp alfa compare to standard care?
At 1500mg weekly, ficerafusp alfa plus pembrolizumab showed an estimated 31% overall survival at three years, described as approximately double the survival seen in a retrospective analysis of standard-of-care pembrolizumab in HPV-negative head and neck cancer.
What did Bicara report about depth of response and long-term outcomes?
Pooled analyses showed deep responders with ≥80% tumor shrinkage had a median duration of response of 31.6 months and median progression-free survival of 36.9 months, with reported 65% and 63% reductions in risks of progression/death and death versus partial responders.
What is ficerafusp alfa and how does it work in solid tumors?
Ficerafusp alfa is a bifunctional antibody targeting EGFR and trapping TGF-β. By directing a TGF-β inhibitor to EGFR-expressing tumor cells, it aims to remodel the tumor microenvironment, improve immune cell infiltration, and drive deep, durable anti-tumor responses.
What are the next clinical steps for Bicara’s ficerafusp alfa program?
Bicara is evaluating 1500mg weekly ficerafusp alfa plus pembrolizumab in the pivotal FORTIFI-HN01 Phase 2/3 trial and plans to start an alternate dosing study with a 12-week loading regimen followed by 2250mg every three weeks in the third quarter of 2026.